Literature DB >> 25493592

Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.

Gert U van Zyl1, Lisa M Frenkel, Michael H Chung, Wolfgang Preiser, John W Mellors, Jean B Nachega.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25493592      PMCID： PMC4784963          DOI： 10.1097/QAD.0000000000000502

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  77 in total

1.  Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Authors:  Lucile Larrouy; C Chazallon; R Landman; C Capitant; G Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; C Katlama; P M Girard; P Yeni; J P Aboulker; F Brun-Vezinet; D Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

2.  Antiretroviral treatment, preexposure prophylaxis, and drug resistance in sub-Saharan Africa: a consensus among mathematical models.

Authors:  Ume L Abbas; Robert Glaubius; Gregory Hood; John W Mellors
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

3.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings.

Authors:  Rami Kantor; Lameck Diero; Allison Delong; Lydia Kamle; Sarah Muyonga; Fidelis Mambo; Eunice Walumbe; Wilfred Emonyi; Philip Chan; E Jane Carter; Joseph Hogan; Nathan Buziba
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

Review 4.  Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review.

Authors:  Kathryn M Stadeli; Douglas D Richman
Journal:  Antivir Ther       Date:  2012-10-10

5.  Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.

Authors:  Gert Uves van Zyl; Thijs E van Mens; Helen McIlleron; Michele Zeier; Jean B Nachega; Eric Decloedt; Carolina Malavazzi; Peter Smith; Yong Huang; Lize van der Merwe; Monica Gandhi; Gary Maartens
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

6.  HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

Authors:  Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Francesca Conradie; Mariette E Botes; Maureen Wellington; Akin Osibogun; Kim C E Sigaloff; Immaculate Nankya; Rob Schuurman; Ferdinand W Wit; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit
Journal:  Lancet Infect Dis       Date:  2011-07-27       Impact factor: 25.071

7.  Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.

Authors:  Gonzague Jourdain; Thor Andrew Wagner; Nicole Ngo-Giang-Huong; Wasna Sirirungsi; Virat Klinbuayaem; Federica Fregonese; Issaren Nantasen; Malee Techapornroong; Guttiga Halue; Ampaipith Nilmanat; Pakorn Wittayapraparat; Veeradet Chalermpolprapa; Panita Pathipvanich; Prapap Yuthavisuthi; Lisa M Frenkel; Marc Lallemant
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

8.  Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.

Authors:  Catherine Orrell; Guy Harling; Stephen D Lawn; Richard Kaplan; Matthew McNally; Linda-Gail Bekker; Robin Wood
Journal:  Antivir Ther       Date:  2007

9.  Protease inhibitor levels in hair strongly predict virologic response to treatment.

Authors:  Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Stephen J Gange; Kathryn Anastos; Alexandra Levine; Charles L Hyman; Mardge Cohen; Mary Young; Yong Huang; Ruth M Greenblatt
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

10.  Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

Authors:  Carole L Wallis; John W Mellors; Willem D F Venter; Ian Sanne; Wendy Stevens
Journal:  AIDS Res Treat       Date:  2010-12-02
View more
  3 in total

1.  Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.

Authors:  Rachel A Silverman; Ingrid A Beck; Catherine Kiptinness; Molly Levine; Ross Milne; Christine J McGrath; Steve Bii; Barbra A Richardson; Grace John-Stewart; Bhavna Chohan; Samah R Sakr; James N Kiarie; Lisa M Frenkel; Michael H Chung
Journal:  J Infect Dis       Date:  2017-12-19       Impact factor: 5.226

2.  Implementation of a point mutation assay for HIV drug resistance testing in Kenya.

Authors:  Horacio A Duarte; Ingrid A Beck; Molly Levine; Catherine Kiptinness; James M Kingoo; Bhavna Chohan; Samah R Sakr; Michael H Chung; Lisa M Frenkel
Journal:  AIDS       Date:  2018-10-23       Impact factor: 4.177

Review 3.  Pooled testing: A tool to increase efficiency of infant HIV diagnosis and virological monitoring.

Authors:  Wolfgang Preiser; Gert U van Zyl
Journal:  Afr J Lab Med       Date:  2020-08-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.